MAP2K7 and glioblastoma: In addition, a full preclinical toxicology package—considering targeted drug delivery strategies such as emerging GBM-targeting nanoparticles [66], if necessary—to decipher safety margins and an optimal therapeutic window of the FAK+MEK inhibitor combination will also build confidence in the clinical potential of FAK+MEK inhibitor combination therapy in GBM.